Showing results (111-120 of 146) with videos related to

Sort By:
Pageof 15
Metabolic Brain Disease|October 15, 2009
Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophreniaSusan J van Rensburg, Cornelius M Smuts, Dinie Hon, et al.
Global Mental Health (Cambridge, England)|September 2, 2025
The concordance between the Montreal cognitive assessment and the repeatable battery for the assessment of neuropsychological status as a cognitive screening tool in a south African community sampleSharain Suliman, Erine Bröcker, Natalie Beath, et al.
Psychiatry Research|February 5, 2021
The course and concomitants of depression in first-episode schizophrenia spectrum disorders: A 24-month longitudinal studyLebogang Phahladira, Laila Asmal, Hilmar K Lückhoff, et al.
Psychological Medicine|April 20, 2022
Antipsychotic treatment effects and structural MRI brain changes in schizophreniaRobin Emsley, Stefan du Plessis, Lebogang Phahladira, et al.
Psychiatric Services (Washington, D.C.)|September 4, 2004
Practical application of pharmacotherapy with long-acting risperidone for patients with schizophreniaSamuel J Keith, Luca Pani, Beat Nick, et al.
The Journal of Clinical Psychiatry|April 11, 2009
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidoneJohn W Newcomer, Robert E Ratner, Jan W Eriksson, et al.
Schizophrenia Research|January 29, 2017
Neurological soft signs in first-episode schizophrenia: State- and trait-related relationships to psychopathology, cognition and antipsychotic medication effectsRobin Emsley, Bonginkosi Chiliza, Laila Asmal, et al.
Early Intervention in Psychiatry|February 2, 2022
The associations of cannabis and methamphetamine use with cognitive performance over the first 2 years of treatment in schizophrenia spectrum disordersFreda Scheffler, Lebogang Phahladira, Chanellé B Hendrikse, et al.
Psychiatry Research|October 31, 2008
Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trialRobin Emsley, Dana J H Niehaus, Petrus P Oosthuizen, et al.
Schizophrenia Bulletin|April 12, 2023
Two Neuroanatomical Signatures in Schizophrenia: Expression Strengths Over the First 2 Years of Treatment and Their Relationships to Neurodevelopmental Compromise and Antipsychotic TreatmentStefan du Plessis, Ganesh B Chand, Guray Erus, et al.
Pageof 15